Arbutus Biopharma (ABUS) Expected to Announce Quarterly Earnings on Wednesday

Arbutus Biopharma (NASDAQ:ABUS) is anticipated to post its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.02) per share and revenue of $0.70 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:30 AM ET.

Arbutus Biopharma (NASDAQ:ABUS) last announced its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported $0.87 earnings per share for the quarter. Arbutus Biopharma had a return on equity of 129.32% and a net margin of 83.95%.The firm had revenue of $179.13 million during the quarter.

Arbutus Biopharma Price Performance

Shares of NASDAQ ABUS opened at $4.34 on Monday. The stock’s 50 day moving average price is $4.53 and its two-hundred day moving average price is $4.41. Arbutus Biopharma has a 52-week low of $3.26 and a 52-week high of $5.38. The stock has a market capitalization of $857.31 million, a P/E ratio of 5.23 and a beta of 0.62.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arbutus Biopharma in a report on Friday, July 17th. Wall Street Zen upgraded Arbutus Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $5.00.

Hedge Funds Weigh In On Arbutus Biopharma

A number of large investors have recently bought and sold shares of ABUS. Oxford Asset Management LLP acquired a new position in Arbutus Biopharma in the second quarter valued at approximately $38,000. Voleon Capital Management LP acquired a new stake in shares of Arbutus Biopharma during the 3rd quarter worth approximately $47,000. Cibc World Markets Corp bought a new stake in shares of Arbutus Biopharma in the 4th quarter worth approximately $48,000. Daiwa Securities Group Inc. lifted its holdings in shares of Arbutus Biopharma by 3,911.1% in the 2nd quarter. Daiwa Securities Group Inc. now owns 15,844 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 15,449 shares during the last quarter. Finally, Prudential Financial Inc. boosted its position in Arbutus Biopharma by 71.5% during the 2nd quarter. Prudential Financial Inc. now owns 18,255 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 7,610 shares during the period. Institutional investors own 43.79% of the company’s stock.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company’s pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core.

In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics.